Literature DB >> 34124556

Carcinoid heart disease of gonadal primary presenting with hypoxia: a case report.

Ronan O'Driscoll1,2, Abhisheik Prashar1,2, George Youssef1,2, Mark Sader1,2.   

Abstract

BACKGROUND: Carcinoid heart disease is a potential sequela of metastatic neuroendocrine tumour that has characteristic valve appearances. Patients can present with symptoms of carcinoid syndrome or be relatively asymptomatic until symptoms of progressive heart failure manifest. CASE
SUMMARY: We present a case of a 54-year-old male who was admitted to the hospital for investigation of hypoxia. Transthoracic echocardiogram was suggestive of carcinoid heart disease which subsequently led to a diagnosis of metastatic neuroendocrine (carcinoid) tumour of the testicular primary. Work-up revealed a patent foramen ovale with evidence of the right to left interatrial shunt from severe tricuspid regurgitation as the cause of his hypoxia. Prior to surgical excision of the primary tumour, percutaneous patent foramen ovale closure was performed resulting in improved arterial oxygen saturation and symptomatic improvement. DISCUSSION: Carcinoid heart disease typically affects the right-sided cardiac valves and the tricuspid valve appearances were critical in leading to a diagnosis of a metastatic neuroendocrine tumour in our patient. This case demonstrates that percutaneous patent foramen ovale closure can be an effective intervention for hypoxia in those not managed surgically. A high index of suspicion should be maintained for gonadal primary carcinoid tumour when there is carcinoid heart disease in the absence of liver metastases.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Case report; Echocardiography; Neuroendocrine tumour; Patent foramen ovale; Shunt; Valvular disease

Year:  2021        PMID: 34124556      PMCID: PMC8189296          DOI: 10.1093/ehjcr/ytaa536

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Characteristic echocardiographic appearances of carcinoid heart disease can aid diagnosis in those not manifesting usual symptoms of carcinoid syndrome A high index of suspicion should be maintained for gonadal primary carcinoid tumour when there is carcinoid heart disease in the absence of liver metastases. Percutaneous patent foramen closure for hypoxia in carcinoid heart disease can be an effective intervention, including in those patients who are not surgically managed.

Introduction

Carcinoid heart disease is a rare condition associated with neuroendocrine (carcinoid) tumours. These tumours typically arise from the gastrointestinal and bronchopulmonary system, although very rarely they have been reported to arise from other sites. Tumour release of circulating vasoactive substances including serotonin metabolites contribute to valvular fibrous plaque formation. This subsequently leads to thickened, shortened, and retracted valve leaflets with associated concurrent valvular stenosis and regurgitation. Patients may be diagnosed after presenting with symptoms of carcinoid syndrome; however, diagnosis is often delayed given the insidious onset of carcinoid heart disease symptoms. We present a unique case of carcinoid heart disease from metastatic neuroendocrine tumour of testicular primary with a coexistent patent foramen ovale (PFO), diagnosed after investigation for hypoxia and successfully managed with percutaneous PFO closure.

Case presentation

A 54-year-old male was admitted from pre-admission clinic for investigation of new-onset hypoxia. He was planned to have an endoscopy for investigation of weight loss, abdominal pain, and diarrhoea. He had additionally reported a history of intermittent palpitations and exertional dyspnoea. Background medical history included hypertension, obesity, type 2 diabetes mellitus, gastro-oesophageal reflux disease, and previous traumatic splenectomy. He was a lifelong non-smoker. Physical examination revealed oxygen saturation of 81% on room air improving to 87% on 4 L via nasal cannula. There was no orthodeoxia. Lung auscultation was unremarkable. There was a Grade 3/6 pansystolic murmur at the left sternal edge associated with jugular venous pressure elevated to the angle of the jaw, with prominent ‘v’ waves and no peripheral oedema. Resting electrocardiogram showed sinus rhythm, rate of 71 beats per minute, normal axis, and no ischaemic changes. Chest X-ray showed clear lung fields. An arterial blood gas on room air showed hypoxia with a mild respiratory alkalosis and elevated alveolar-arterial (A-a) oxygen gradient (). Haemoglobin and renal function were normal. Computed tomography (CT) pulmonary angiogram on admission revealed normal lung parenchyma and a left posterior basal segmental pulmonary embolism without evidence of right heart strain, the size of which was thought to inadequately account for the hypoxia. Pulmonary function testing showed a mild restrictive pattern with FEV1 2.44 L (70% predicted), FVC 3.22 L (73% predicted), FEV1/FVC 75.90% (99% predicted), and carbon monoxide transfer coefficient 4.38 mL/(min*mmHg*L) (103% predicted), although there was variable performance in testing. Initial arterial blood gas Transthoracic echocardiogram (TTE) showed the normal left ventricular size and systolic function. There was mild bi-atrial dilatation along with mild right ventricular dilatation (44 mm basal diameter) with hyperdynamic systolic function. Tricuspid annular plane systolic excursion was 30 mm. Tricuspid valve leaflets were noted to be thickened, immobile and retracted, not coapting in systole with free-flowing tricuspid regurgitation, which in the setting of a morphologically normal mitral valve was pathognomonic for carcinoid heart disease (, Video 1 and Supplementary material online, ). The pulmonary valve had a normal appearance and mild regurgitation. Twenty-four hour urinary 5-hydroxyindoleacetic acid was elevated at 260 µmol/24 h (normal range 0–30), whilst chromogranin A was 156 ng/mL (normal range 0–104).
Figure 1

Transthoracic echocardiogram. Apical four-chamber zoomed tricuspid valve view, showing thickened and stenosed tricuspid valve leaflets in mid-systole (A), with colour Doppler showing free-flowing tricuspid regurgitation (B). Apical four-chamber tricuspid regurgitation spectral Doppler demonstrating typical ‘dagger’ shaped waveform (C). RA, right atrium; RV, right ventricle.

Transthoracic echocardiogram. Apical four-chamber zoomed tricuspid valve view, showing thickened and stenosed tricuspid valve leaflets in mid-systole (A), with colour Doppler showing free-flowing tricuspid regurgitation (B). Apical four-chamber tricuspid regurgitation spectral Doppler demonstrating typical ‘dagger’ shaped waveform (C). RA, right atrium; RV, right ventricle. A TTE bubble study (Video 2) was performed due to radiographically normal lungs, the small size of the pulmonary embolism, and patient reluctance for a transoesophageal echocardiogram (TOE), which were strongly positive within three cardiac cycles suggesting shunt at the cardiac level. However, the passage of bubbles appeared to originate from the pulmonary veins which was suspicious for pulmonary shunting. Dedicated digital subtraction pulmonary angiography (Supplementary material online, ) was therefore performed which excluded pulmonary arteriovenous fistula and large pulmonary embolism but revealed early filling of the left atrium confirming an intracardiac shunt. The patient eventually agreed to a TOE (, Supplementary material online, ) with bubble study (, Video 3) which confirmed a long tunnel patent foramen ovale with an aneurysmal interatrial septum. There was evidence of the significant right to left shunting on colour Doppler at rest in the supine position.
Figure 2

Transoesophageal echocardiogram. Mid-oesophageal interatrial septum view showing patent foramen ovale (A) and colour Doppler with right to left shunt (B). Transoesophageal echocardiogram bubble study demonstrating origin of bubbles from patent foramen ovale, without involvement of left upper pulmonary vein (C). Ao, aorta; LA, left atrium; PFO, patent foramen ovale; RA, right atrium.

Transoesophageal echocardiogram. Mid-oesophageal interatrial septum view showing patent foramen ovale (A) and colour Doppler with right to left shunt (B). Transoesophageal echocardiogram bubble study demonstrating origin of bubbles from patent foramen ovale, without involvement of left upper pulmonary vein (C). Ao, aorta; LA, left atrium; PFO, patent foramen ovale; RA, right atrium. 68-Gallium DOTATATE PET scan. 68-Gallium DOTATATE PET scan demonstrating avid uptake in retroperitoneal lymph node and right testicle (red arrows). Left upper quadrant uptake secondary to previous splenectomy. 68-Gallium DOTATATE PET () and CT imaging identified a 27 mm × 36 mm × 57 mm avid retroperitoneal para-aortic lymph node and avid right testicular mass. Percutaneous biopsy of the retroperitoneal mass revealed a well-differentiated neuroendocrine (carcinoid) tumour WHO Grade 1. Prior to excision biopsy of the right testicular tumour, consideration of surgical tricuspid valve replacement combined with PFO closure was declined by the patient. Given marked resting hypoxia, need for surgery and undetermined diagnosis and prognosis, percutaneous closure of the patent foramen ovale was considered appropriate. Pre-procedural right heart catheterization demonstrated a right to a left atrial pressure gradient (). The PFO was successfully closed under fluoroscopic guidance with a 30 mm Amplatzer PFO Occluder device (Supplementary material online, ). Pre-procedural arterial oxygen saturation of 82% improved to 88% immediately post-procedure. There were no procedural complications. Pre-procedural right heart catheterization pressures The patient underwent an inpatient orchidectomy with histopathology of the right testicle confirming a primary well-differentiated neuroendocrine (carcinoid) tumour. The patient was commenced on somatostatin analogue therapy. He was discharged a week following PFO closure with arterial oxygen saturation of 92% on room air. He has had durable relief of his symptoms. Repeat TTE showed no residual flow across the interatrial septum. The patient continues to decline consideration of tricuspid valve surgery.

Discussion

This educational and rare case describes a patient with newly diagnosed carcinoid valvular heart disease secondary to primary testicular neuroendocrine tumour (NET) discovered after investigation for hypoxia. The classic appearance of carcinoid heart disease on TTE was key to guiding further investigation to confirm the diagnosis in our patient. Right-sided valvular disease is the most common manifestation of carcinoid heart disease with the tricuspid valve most frequently involved, while left heart valvular disease is rare in the absence of a PFO with right to left shunting or bronchopulmonary tumour. The patient’s hypoxia was explained by right to left intracardiac shunting through a PFO, secondary to severe regurgitation from the carcinoid-affected tricuspid valve, with potential mechanisms including both right atrial pressure elevation and preferentially directed venous blood flow across the interatrial septum from the regurgitant jet. Our case demonstrates the importance of assessment for PFO in those diagnosed with carcinoid heart disease and unexplained hypoxia. International consensus guidelines for the diagnosis and management of carcinoid heart disease published in 2017, recommend that patients be referred for consideration of valve surgery when there is severe regurgitation and development of symptoms or evidence of early right ventricular dysfunction, as was the case with our patient. These guidelines also recommend PFO closure at the time of valve surgery. Our case highlights that even in those not managed with surgical valve replacement initially, percutaneous catheter-based closure of patent foramen ovale is a reasonable, minimally invasive option for a significant right to left interatrial shunt causing hypoxia. Neuroendocrine tumour of testicular primary remains exceedingly rare. While our patient only had metastasis to a retroperitoneal lymph node, other metastatic sites including liver, lung, vertebrae, heart, and contralateral testicle have been reported in those with testicular carcinoid. It is interesting that our case has presented with carcinoid heart disease in the absence of significant metastatic burden, given it is typically associated with liver metastases. It has been reported that because venous drainage from the ovaries bypass the portal circulation, this may explain why primary ovarian carcinoid can present with carcinoid heart disease without liver metastases. Theoretically this should also be true for primary testicular carcinoid tumours, although it is ultimately unknown.

Lead author biography

Ronan O'Driscoll is a Basic Physician Trainee at St George Hospital in Sydney, Australia. He will soon commence as a Cardiology Registrar at The Canberra Hospital. He also has an ongoing interest in global health.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online. Click here for additional data file.
Day 1Pre-admission clinic for elective endoscopy, subsequently referred to emergency department after anaesthetist notes hypoxia. Computed tomography pulmonary angiogramshows left basal pulmonary embolism.
Day 5Transthoracic echocardiogram (TTE) with valve appearances suspicious for carcinoid heart disease
Day 8Seen by medical oncology team
Day 9Discharge from hospital against medical advice
Day 2968-Gallium DOTATATE positron emission tomography (PET) showing avid para-aortic lymph node and right testes
Day 42Para-aortic lymph node computed tomography-guided biopsy confirms carcinoid tumour
Day 50TTE bubble study strongly positive within three cardiac cycles
Day 53Admitted to hospital with dyspnoea
Day 58Digital subtraction pulmonary angiography confirms atrial level shunt
Day 62Declined further investigation, discharged from hospital
Day 71Agreed to transoesophageal echocardiogram with bubble study, confirms patent foramen ovale (PFO)
Day 93Reluctant for surgery, multidisciplinary decision to proceed with percutaneous PFO closure, directly admitted to hospital
Day 96PFO closure performed
Day 97No residual interatrial flow on repeat TTE
Day 99Right orchidectomy performed
Day 103Discharged from hospital
Day 170Stable symptoms at follow-up
Table 1

Initial arterial blood gas

MeasurementValueNormal values
pH7.504(7.35–7.45)
pO248.7 mmHg(75–100 mmHg)
pCO228.1 mmHg(35–45 mmHg)
HCO321.9 mmol/L(22–26 mmol/L)
Base excess−0.8 mmol/L(±2 mmol/L)
Inspired oxygen (FiO2)21%
A-a gradient66.0 mmHg(17.5 mmHg)
Table 2

Pre-procedural right heart catheterization pressures

SitePressure (mean) (mmHg)Normal values for mean pressure (mmHg)Heart rate (beats per minute)
Left atrium14/14 (11)(4–12)73
Right atrium20/21 (16)(0–7)72
Inferior vena cava22/24 (21)(1–10)71
  10 in total

Review 1.  Carcinoid heart disease: presentation, diagnosis, and management.

Authors:  David J Fox; Rajdeep S Khattar
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

2.  Left heart involvement with cardiac shunt complicating carcinoid heart disease.

Authors:  M J Millward; M P Blake; M J Byrne; J Hung; P Gibson
Journal:  Aust N Z J Med       Date:  1989-12

Review 3.  Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.

Authors:  Joseph Davar; Heidi M Connolly; Martyn E Caplin; Marianne Pavel; Jerome Zacks; Sanjeev Bhattacharyya; Daniel J Cuthbertson; Rebecca Dobson; Simona Grozinsky-Glasberg; Richard P Steeds; Giles Dreyfus; Patricia A Pellikka; Christos Toumpanakis
Journal:  J Am Coll Cardiol       Date:  2017-03-14       Impact factor: 24.094

Review 4.  Carcinoid heart disease.

Authors:  Saamir A Hassan; Jose Banchs; Cezar Iliescu; Arvind Dasari; Juan Lopez-Mattei; Syed Wamique Yusuf
Journal:  Heart       Date:  2017-06-08       Impact factor: 5.994

5.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

6.  Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

Authors:  P A Pellikka; A J Tajik; B K Khandheria; J B Seward; J A Callahan; H C Pitot; L K Kvols
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

7.  Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI.

Authors:  Sanjeev Bhattacharyya; Christos Toumpanakis; Margaret Burke; Andrew M Taylor; Martyn E Caplin; Joseph Davar
Journal:  Circ Cardiovasc Imaging       Date:  2009-11-17       Impact factor: 7.792

8.  Carcinoid heart disease associated with primary ovarian carcinoid tumor.

Authors:  Nithima Chaowalit; Heidi M Connolly; Hartzell V Schaff; Maurice J Webb; Patricia A Pellikka
Journal:  Am J Cardiol       Date:  2004-05-15       Impact factor: 2.778

Review 9.  Carcinoid tumours of the testis.

Authors:  Otto B Stroosma; Karl P J Delaere
Journal:  BJU Int       Date:  2008-01-08       Impact factor: 5.588

Review 10.  Carcinoid heart disease.

Authors:  Heidi M Connolly; Patricia A Pellikka
Journal:  Curr Cardiol Rep       Date:  2006-03       Impact factor: 2.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.